Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma

Biliary tract carcinomas (BTC) are malignant tumors with limited therapeutic options. Clinical experiences with anti-EGFR therapies have produced unsatisfactory results. The strategies of combined inhibition of EGFR and MEK1/2 could be a promising therapeutic option in BTC treatment. Preclinical act...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Cavalloni, Giuliana, Peraldo-Neia, Caterina, Varamo, Chiara, Chiorino, Giovanna, Sassi, Francesco, Aglietta, Massimo, Leone, Francesco
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5239557/
https://ncbi.nlm.nih.gov/pubmed/27429047
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10587
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items